MetrioPharm AG

MetrioPharm AG is located in Zürich, Switzerland on Bleicherweg 10. MetrioPharm AG is rated 3 out of 5 in the category pharmaceutical company in Switzerland. MetrioPharm is a pharmaceutical biotech company developing the first effective and safe therapy for chronic immune disorders. Our focus is on Immune Mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis and multiple sclerosis. MetrioPharm’s lead compound MP1032 is currently in phase II clinical testing. MetrioPharm was founded in 2007. The company is headquartered in Zurich and operates a research facility in Berlin. Our team consists of scientists and managers with several years of experience in the development of pharmaceutical products. Together with first-class partners, we have established an efficient development process – from the preclinical stage, until licensing and marketability. Thanks to the expertise and passion of our employees, we achieved important milestones repeatedly before the set schedule.